Buffalo Business First reports that Cleveland BioLabs Inc. is getting closer to FDA approval for its drug that treats the gastrointenstinal effects of acute radiation syndrome.
Cleveland BioLabs has been awarded several contracts, both with the Biomedical Advanced Research and Development Authority and from the Department of Defense. These contracts play a major role in paying for the company’s expenses. The total contract value for
No comments:
Post a Comment